Bank of America Securities Maintains a Buy on Incyte Corporation (INCY)

Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Fye associated the rating with the company’s market position and cur ...